Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label bosutinib treatment extension in CML patients from B1871006 or B1871008
2013-000691-15Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by Pfizer. Started May 2013; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-000691-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000691-15.